Department of Human Nutrition, University of Moncton, Moncton, New Brunswick, Canada.
J Am Coll Nutr. 2010 Aug;29(4):419-29. doi: 10.1080/07315724.2010.10719859.
This investigation on a homogenous cohort of young adult Caucasian type 1 diabetic (IDDM) patients (1) aimed at studying the occurrence of low bone mineral density (BMD) at an early stage prior to menopause (i.e., during the first decade after peak bone mass) and (2) elucidating the possible mechanisms underlying IDDM-induced bone complication.
Twenty-seven female patients with insulin-treated and well-controlled diabetes, without renal complications, and 32 well-matched healthy controls, aged between 30 and 40 years and fulfilling rigorous inclusion criteria to minimize bone-confounding factors, were enrolled. Areal BMD was evaluated by dual energy X-ray absorptiometry at axial (lumbar spine) and appendicular (femur) sites, using diagnostic WHO reference (T-scores). Osteoblast functions, bone metabolism, related key minerals, and 2 osteoclast-stimulating calciotropic hormones regulating their serum levels were assessed biochemically.
The number of cases with low BMD (T-score below -1.1 SD) was almost 2-fold greater (p < 0.01) in the IDDM group. BMD was significantly lower in this group for 3 lumbar sites (p < 0.01) and femur Ward's triangle (p < 0.05). Bone formation was reduced, as evidenced by the suppressions of osteocalcin (OC; p < 0.01) and IGF-I (p < 0.001). However, bone alkaline phosphatase (bALP) was induced (p < 0.01), in contrast to what is usually observed in cases of reduced bone formation. Correlated total ALP activity was also significantly increased. There was no change in the specific marker of bone resorption (urinary deoxypyridinoline). Serum calcium was significantly elevated, particularly after adjustment for albumin (p < 0.001), despite lower 1,25(OH)(2)D(3) (p < 0.001) and no elevation of PTH. All significant bone-related biochemical changes were significantly correlated with glycosylated hemoglobin, a clinical indicator of long-term glycemic control, indicating a direct effect of the disease.
Bone loss in the IDDM group results from a decrease in bone formation rather than an increase of bone resorption. The induction of bALP is indicative of impaired osteoblast differentiation and maturation, which delayed (down-regulated) later stages of matrix mineralization, as evidenced by lower OC and BMD.
本研究旨在(1)调查同批年轻的高加索白人 1 型糖尿病(IDDM)患者,在绝经前(即峰值骨量后 10 年内)发生低骨密度(BMD)的情况;(2)阐明 IDDM 引起的骨并发症的可能机制。
共纳入 27 名接受胰岛素治疗且血糖控制良好、无肾脏并发症的女性患者和 32 名年龄在 30 至 40 岁且符合严格纳入标准的健康对照者,以尽量减少骨相关混杂因素。采用双能 X 线吸收法(DXA)对轴向(腰椎)和附肢(股骨)部位的骨密度进行检测,使用诊断 WHO 参考标准(T 评分)。通过生化方法评估成骨细胞功能、骨代谢、相关关键矿物质和调节其血清水平的 2 种破骨细胞刺激钙调节激素。
IDDM 组低 BMD(T 评分低于-1.1 SD)的病例数几乎增加了 2 倍(p < 0.01)。该组 3 个腰椎部位(p < 0.01)和股骨 Ward 三角区(p < 0.05)的 BMD 明显降低。骨形成减少,表现为骨钙素(OC;p < 0.01)和 IGF-I(p < 0.001)的抑制。然而,骨碱性磷酸酶(bALP)被诱导(p < 0.01),与通常在骨形成减少的情况下观察到的情况相反。相关的总 ALP 活性也显著增加。骨吸收的特异性标志物(尿脱氧吡啶啉)没有变化。血清钙显著升高,尤其是在调整白蛋白后(p < 0.001),尽管 1,25(OH)(2)D(3)降低(p < 0.001),PTH 没有升高。所有显著的骨相关生化变化均与糖化血红蛋白显著相关,糖化血红蛋白是血糖长期控制的临床指标,表明疾病的直接影响。
IDDM 组的骨丢失是由骨形成减少而不是骨吸收增加引起的。bALP 的诱导表明成骨细胞分化和成熟受损,这延迟(下调)了基质矿化的后期阶段,表现为 OC 和 BMD 降低。